Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration
about
Direct Oral Anticoagulants for the Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: Understanding Differences and SimilaritiesLong-term prescribing of new oral anticoagulantsReducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation With Direct Oral Anticoagulants. Is One Of These Not Like The Others?Impact on Drug Safety of Variation in Adherence: The Need for Routinely Reporting Measures of Dose Intensity in Medication Safety Studies Using Electronic Health Data.Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AFAntithrombotic treatment in elderly patients with atrial fibrillation: a practical approach.Transforming the care of atrial fibrillation with mobile health.Use of direct oral anticoagulants for the prevention and treatment of thromboembolic disease in patients with reduced renal function: a short review of the clinical evidenceDoes the association between adherence to statin medications and mortality depend on measurement approach? A retrospective cohort studyDirect-acting oral anticoagulants: pharmacology, indications, management, and future perspectives.Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort studyAdherence to oral anticoagulants in patients with atrial fibrillation-a population-based retrospective cohort study linking health information systems in the Valencia region, Spain: a study protocol.Patient-Reported Treatment Satisfaction with Rivaroxaban for Stroke Prevention in Atrial Fibrillation. A French Observational Study, the SAFARI Study.Innovative designs of point-of-care comparative effectiveness trials.Persistence of non-vitamin K antagonist oral anticoagulant use in Japanese patients with atrial fibrillation: A single-center observational study.Predictors of gastrointestinal bleeding among patients with atrial fibrillation after initiating dabigatran therapy.Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial FibrillationAtrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms.The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) : Exploring the changes in anticoagulant practice in patients with non-valvular atrial fibrillation in the Netherlands.Warfarin versus dabigatran etexilate: an assessment of efficacy and safety in patients with atrial fibrillation.Target-specific oral anticoagulants and the hospitalist.Edoxaban for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.Real-World Adherence and Persistence with Direct Oral Anticoagulants in Adults with Atrial Fibrillation.Use of direct oral anticoagulants in patients with atrial fibrillation in Scotland: Applying a coherent framework to drug utilisation studies.Adherence with direct oral anticoagulants in nonvalvular atrial fibrillation new users and associated factors: a French nationwide cohort study.Non-vitamin K antagonist oral anticoagulants: impact of non-adherence and discontinuation.The challenges and limitations of widespread direct oral anticoagulant treatment: practical suggestions for their best use.Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2.Adherence to long-term anticoagulation treatment, what is known and what the future might hold.A Summary of the Literature Evaluating Adherence and Persistence with Oral Anticoagulants in Atrial Fibrillation.Factors Affecting Patients' Perception On, and Adherence To, Anticoagulant Therapy: Anticipating the Role of Direct Oral Anticoagulants.Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation.Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study.Incorporating Comprehensive Management of Direct Oral Anticoagulants into Anticoagulation Clinics.Patient satisfaction with extended-interval warfarin monitoring.Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation.Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration.Indications for suboptimal low-dose direct oral anticoagulants for non-valvular atrial fibrillation patientsBeliefs about medicines and non-adherence in patients with stroke, diabetes mellitus and rheumatoid arthritis: a cross-sectional study in ChinaPrognosis and treatment of atrial fibrillation patients by European cardiologists: one year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry).
P2860
Q26787046-17459043-4DC1-449A-860B-F33FB7EC9874Q28069821-F3B23EA7-0410-49AA-8337-40279D086500Q28077755-E1FEC201-A649-49C8-A7C0-6A4BFDC3FBB1Q30994474-B2D31764-9220-41E3-AA9A-88EF59B4F9D0Q31054764-5657CDAE-D8D6-4731-8A49-74E0AE2FB82BQ33427274-61F0FEF5-C653-459A-9DA4-3740AC506358Q33449196-F29BB7EE-732F-42D2-9EA0-4DD1779A59E5Q33553657-8D358D1C-5618-4828-B880-2033C09E94C1Q33582496-918A1288-26D1-4CD6-B3F4-796E335B81F1Q34670808-090C5383-4040-4E97-8936-AAD1E0598D39Q36085794-3EF5CEBC-8E0B-4DE8-915D-E9CC0D0A7877Q36179688-C986FAED-57B5-4A40-BD6C-1086EC5BB739Q36217719-7E5761BD-F317-4117-90F4-E22C70C53A10Q36264914-6B9703E1-82F5-4A63-8D84-A10771EE2F3DQ36352841-028E2962-6632-4CE7-B3FF-C384FE8874B4Q36571742-54062FA5-F060-4EE3-A38F-A953EB83B4B0Q36714127-746CE65E-4CE7-4B43-A32E-039503B97115Q36956791-9F7B823A-D30A-48E2-A5E3-FC44A6D84A28Q37289894-7CC6E37C-536F-4540-B64B-CB5F2C570FCAQ38262325-D2CB22AE-1D33-4054-A7E7-FCF2BEEDFD74Q38307541-7E2B6CE1-4463-44B0-8F92-178D29F3894AQ38630768-5D95D58C-CE70-4356-A058-0E94AFF83E1EQ38653946-65CDDD84-F6DF-47F2-B881-CE7EACEE0C26Q38655829-5E772C20-4BF3-475F-AC4D-F48BAF77F88CQ38655951-012B8F96-47BF-40DA-A6F7-9D4A6CCE1183Q38662571-81E9A2D8-9DAB-4A01-B28F-EC080574B4ABQ38664920-23A793D8-6F33-4E46-9497-CD7734A563EAQ38723869-4ECCCFC4-87DE-4C49-AD95-910AFAA7103FQ38833151-650BAE88-AC9C-4E81-8FCC-D2B5076521B2Q38854836-8A1DF2C5-48CC-4A1C-995A-5168CA3A81B2Q38903357-8B1B2BEE-8BFE-4921-BEEF-5EE09C4C6F25Q39129273-0789B053-FB55-4247-8DBB-FB11391B430BQ39385409-92347E94-A25D-47FD-9D53-5892B8C64051Q39449914-8380B4E1-19C9-4BC0-8549-EF6BF8984F40Q39717056-58375F30-ECFD-4C7C-BABC-A31D485082FBQ40267269-DCD7C463-991C-41B1-9A84-F336A5B64ABFQ41594904-F2EE004A-7B27-48E2-87B5-28D9C36635B2Q42244714-68A20F6A-4BDF-4373-A7E0-CADB6659360CQ42376801-F589B26F-528C-4A92-A9F6-AE3967FB45B2Q43630565-C49BC394-DE3D-4D76-A42D-7121091450B7
P2860
Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 April 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Adherence to dabigatran therap ...... veterans health administration
@en
Adherence to dabigatran therap ...... eterans health administration.
@nl
type
label
Adherence to dabigatran therap ...... veterans health administration
@en
Adherence to dabigatran therap ...... eterans health administration.
@nl
prefLabel
Adherence to dabigatran therap ...... veterans health administration
@en
Adherence to dabigatran therap ...... eterans health administration.
@nl
P2093
P2860
P1476
Adherence to dabigatran therap ...... veterans health administration
@en
P2093
Anna E Barón
Cynthia A Jackevicius
Evan P Carey
Fran Cunningham
Gary K Grunwald
John S Rumsfeld
Lucas N Marzec
Mintu P Turakhia
P Michael Ho
Paul D Varosy
P2860
P304
P356
10.1016/J.AHJ.2014.03.023
P407
P577
2014-04-05T00:00:00Z